Prostate cancer: Adaptive, biomarker-driven platform trial shows that new hormonal agents have better efficacy for mCRPC
At ESMO 2023 Henrik Grönberg, presented the ProBio study. He discussed the study design – which is described as an outcome-adaptive biomarker-driven platform trial – and the results of the study. The results demonstrate the superiority of new hormonal agents over taxanes in terms of progression-free survival and overall survival. This has significant implications for the treatment of metastatic prostate cancer, suggesting that new hormonal agents should be considered before taxanes and that platform trials like ProBio may represent the future of oncology research.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.